AMR_Action_Fund
Boehringer Ingelheim joins AMR Action Fund to support antibiotic R&D
Search
Partnering pet therapeutics
Learn more about our research focus and our most recent partnerships regarding pet therapeutics.
New treatment for chronic kidney disease approved in the EU
The European Commission (EC) has approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease
Largest European development center for biotechnology
Boehringer Ingelheim inaugurates largest European development center for biotechnology
Development Biotechnology sustainable cell culture
Boehringer Ingelheim refines its bioprocess technology operations in Animal Health with greater focus on environmental sustainability to reduce footprint
ATM-Ranking-2021
Boehringer Ingelheim climbs two places. New early-stage research projects for disease areas relevant to low-to-middle income countries not reflected.
BI_X_Shanghai
Boehringer Ingelheim opens a second branch of its digital lab in Shanghai
Brazil boosts biosecurity in dairy farms
We partnered with Embrapa to help farmers and local authorities set best practices in biosecurity for dairy through a biosecurity certificate.
EMPRISE-Study
EMPRISE-Study
Scam alert
A recruitment scam involving Boehringer Ingelheim is circulating.
European Election: Europe needs our vote
This week, over 400 million citizens from the 27 European Union (EU) Member States will be able to elect a new European Parliament. Our vote can help to make a better and stronger Europe..
Patient Organizations
Boehringer Ingelheim’s core principles and vision guide our work with patient organisations.
Boehringer Olaf Scholz break ground for innovation center
Boehringer Ingelheim and German Chancellor Olaf Scholz lay the foundation stone for 285 million EUR innovation center
Breakthrough in Artificial Intelligence ChatGPT
Is ChatGPT the AI revolution we were waiting for or only media hype? Experts from Boehringer Ingelheim take a close look.
Second cancer immunotherapy partnership with 3T Bio
Second cancer immunotherapy partnership with 3T Bio
Accelerating new cancer medicines in partnership with CBmed
Boehringer Ingelheim and CBmed join forces to translate novel cancer therapy approaches faster into new medicines for patients
India: Many positive developments for the population
A conversation with interim country manager Sandip Agrawal about a young and growing country
Chronic kidney disease in cats
Detect and manage chronic kidney disease and high blood pressure in cats
Boehringer Ingelheim 2022 half year results
First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Combating complex diseases with data
How does big data create disrupting insights for our company? Read about potential use cases and promoting a data mindset
FreVAX smartphone application piglet vaccination
New FreVAX™ smartphone application brings piglet vaccination to another level
FDA-approves-nintedanib-in-SSc-ILD
FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
STOP Rabies: moving towards elimination
Rabies still kills thousands of people every year. However, rabies is 100 percent vaccine preventable. We contribute to eliminating the disease.
vet scholars symposium
Veterinary students and researchers from 38 veterinary schools in North America and Europe gathered at the NIH in August to discuss the future of veterinary medicine.
Major investment for respiratory diseases completed
105 million euros invested into expansion of production facilities in Ingelheim and Dortmund